Case studies
Working with our customers to reduce time to market, deliver on quality, provide deep therapeutic expertise, and enhance R&D ROI.
Highlights
We focus our innovation on the factors that matter most — accelerating time to market, reducing costs and enhancing quality. Learn more about how we've helped clients meet and exceed their goals in this selected library of case studies.
Proactive patient retention strategy in a GLP-1 RA trial
Explore how ICON successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.
A small biotech success story
A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.
FSP partnership - sustained efficiency and ongoing innovation
The implementation of an FSP model across our partner's project management function, led to 20% cost efficiences and a 30% reduction in client burden.
By taking a site and patient-centric approach, and leveraging advanced tools and real-time data insights, we maximise patient access, recruitment, and retention—ensuring that every trial is conducted with efficiency, agility, and a commitment to improving patient outcomes.
All case studies
Filter our case studies by categories, selecting amongst our broad range of solutions.
Automating EDC user access for improved trial efficiency
This case study demonstrates how ICON automated EDC user access management using API integrations and workflow automation, enhancing efficiency, security, compliance, and scalability in clinical trials while reducing costs and delays.
Enhancing the impact of scientific posters
The ICON global medical communications group worked with a large pharmaceutical company to identify ways to engage the congress audience and expand the impact of their scientific presentations at a large international meeting.
Pain proof of concept
ICON had he objective to develop a smartwatch mobile app combination that can be used to alert patients, and physicians and drug development teams to physical behaviours that may exacerbate patients’ pain.
.jpg?crop=yes&w=2016&h=1060&a=0,142&itok=N0MD5hp7 "Doctor consultation with study participant"){kind=icon}
Allergic rhinitis
A Biotech client contracted ICON to conduct a Phase III study that was a double-blinded, randomised, multinational, multicentre, placebo-controlled trial.
Triple negative breast cancer
A large, multinational pharmaceutical company needed to better understand patient perspectives to optimize protocol and study design and operationalise a study for TNBC.
Successes in phase 2 autologous cellular therapy Oncology programme
ICON was awarded two early development cancer immunotherapy studies from a biotherapeutic company for a potentially ground¬breaking autologous cellular therapy in the treatment of two tumour types.
Study in type 1 diabetes patients
Sponsor proposed a randomized, open-label, multi-centre, parallel-group study comparing the safety and efficacy of STUDY DRUG with Novolog in type 1 diabetes (T1D) patients.
Severe COPD phase III case study
A sponsor conducting an international Phase III program of two double-blind, randomised studies consulted ICON’s respiratory experts for assistance in patient enrolment, and study planning and monitoring.
Complex, early-phase study in Huntington’s disease
ICON was contracted to conduct an early-phase clinical trial in Huntington’s disease across 12 countries and 53 sites.
Long-term follow-up study for rare disease gene therapy
ICON provided full-service support to a large biotech company in two global Phase 3 trials for a gene therapy product treating spinal muscular atrophy (SMA), a rare but serious condition causing muscle wasting and weakness.
Trial decentralisation
Clinical trial participation exposes rare disease participants to significant pressure financially, logistically and psychologically, and these incremental pressures can negatively impact a patient’s ability or willingness to enrol or remain in a clinical trial.
Rapid mobilisation to advance COVID-19 treatment development
In February 2020 ICON quickly mobilised its vaccine and infectious disease resources to assist government
and commercial clients in addressing the COVID-19 global threat.
and commercial clients in addressing the COVID-19 global threat.
Let's collaborate
Discover how ICON's expertise transforms clinical trials.